Reading Time: 2 minutesThe International Symposium on ALS/MND has closed its doors after three insightful, inspiring and hopeful days! This year’s event in San Diego really has showcased the breadth of research happening around the
Search Results for: clinical trial
Reading Time: < 1 minuteIn the session on therapeutic strategies and treatment approaches, we’ve heard seven talks about new therapies being developed and new ways to find possible treatments. One talk was
Reading Time: 2 minutesThe Preclinical and Prodromal ALS session focused on early diagnosis of MND and the use of biomarkers to reveal early signs of the disease. A key approach to this type of research is to use a
36th Symposium: San Diego Causes and disease mechanisms Markers of Disease Progression MND Research Models of MND Symposium Treatments
Finding new treatments for MND
Reading Time: 6 minutesThe global MND research community is once again preparing for one of the most anticipated events of the year—the 36th International Symposium on ALS/MND. This annual
Reading Time: 5 minutesIn our previous blog, we took a walk through the early stages of the research journey, learning how researchers discover new things about MND and
Reading Time: 7 minutesHave you ever wondered what life in the lab really looks like? Who are the people working tirelessly to understand MND and find effective treatments
Reading Time: 5 minutesBy Oscar Wilkins, Non-Clinical Research Fellow, University College London and The Francis Crick Institute Hi, I’m Oscar, a newly appointed Lady Edith Wolfson Non-Clinical Research
Reading Time: 6 minutesMND EnCouRage UK is our annual event which aims to celebrate and support the work of researchers who are just beginning their careers in MND,
Reading Time: 7 minutesIn our previous blog, we explained what biomarkers are and what they can be used for. In this blog, we dive further into the world
Reading Time: 6 minutesMND doesn’t just affect movement – it can also impact thinking and behaviour. But these cognitive changes in MND aren’t the same for everyone. In